ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
Retrieved on:
Tuesday, January 25, 2022
Degenerative disease, Professional, Parent, III, Institute, CEO, Li Yan (Wu), Growth, RNA, Trial of the century, Trust, Pharmacokinetics, ADHD, Attention deficit hyperactivity disorder, Partnership, Roche, Trachea, Breathe Me, Asthma, Epithelium, Phase, Respiratory syncytial virus, Microbiology, Death, Safety, Cell death, NMPA, Scripps Research, Population, Respiratory disease, Hospital, Chinese New Year, Fever, Pi, Wheeze, WHO, Cell fusion, Patient, Marketing, Drug discovery, Infant, Cough, GLOBE, FDA, RSV, Pharmaceutical industry, Vaccine, Fine chemical, Genentech
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir (AK0529) for the treatment of respiratory syncytial virus (RSV) infection in a Phase III registration clinical trial.
Key Points:
- SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir (AK0529) for the treatment of respiratory syncytial virus (RSV) infection in a Phase III registration clinical trial.
- The Phase III trial, named AIRFLO, is designed to evaluate clinical efficacy, safety, tolerance, pharmacokinetics, and antiviral effect of ziresovir in hospitalized infants and children with RSV infection.
- This is the first time ever that a phase III clinical trial of an RSV-specific therapeutic has been completed.
- The successful completion of patient enrollment and dosing in the AIRFLO study could not have been achieved without the dedication and diligence of our ArkBio team.